Esketamine alleviated cardiomyocyte ferroptosis induced by oxygen-glucose deprivation/reoxygenation (OGD/R) via cyclic GMP-AMP synthase interactor.
Cytotechnology April 1, 2025 Jianjun Ouyang, Weiqiang Xiao, Di Wu et al. 8 citations
In patients undergoing total knee arthroplasty, tourniquet use causes limb ischemia-reperfusion injury that releases inflammatory cytokines and reactive oxygen species, leading to myocardial damage. In a randomized trial with 23 patients, those receiving 0.5 mg/kg esketamine alongside conventional anesthesia showed higher levels of the antioxidants glutathione peroxidase and glutathione, and lower levels of inflammatory markers IL-6 and TNF-α, oxidative stress marker malondialdehyde, iron (Fe2+), and cardiac injury markers creatine kinase, CK-MB, and lactate dehydrogenase, compared to controls. In cell experiments, esketamine reduced oxygen-glucose deprivation/reperfusion-induced increases in malondialdehyde, Fe2+, and reactive oxygen species, and prevented decreases in glutathione peroxidase, glutathione, GPX4, and FTH1; these effects were reversed by overexpressing STING. Esketamine appears to alleviate cardiomyocyte ferroptosis via STING, which may explain its protective effect against myocardial injury from tourniquet-induced ischemia-reperfusion.